Previous 10 | Next 10 |
Trevena (NASDAQ:TRVN) is scheduled to announce Q4 earnings results on Thursday, March 31st, before market open. The consensus EPS Estimate is -$0.09 (-12.5% Y/Y) and the consensus Revenue Estimate is $0.46M (+557.1% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions...
ACTG, AFMD, OTCPK:BRPHF, OTCQX:CBWTF, CLSN, GOED, LTRY, NNDM, NNOX, PDSB, PLX, PTR, TRVN, WBA For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open
CHESTERBROOK, Pa., March 30, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financi...
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
CHESTERBROOK, Pa., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President &a...
Submission supported by data from a Phase 3 bridging study of oliceridine injection compared to IV morphine, conducted in China by Nhwa Trevena is eligible to receive future success payments upon approval and commercialization milestones, as well as a 10% royalty on net sa...
CHESTERBROOK, Pa., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President &a...
Trevena continues to struggle to get OLINVYK off the launch pad. COVID-19 headwinds are persisting, and it is having an impact on the company's ability to get through P&T committees. Trevena is building a body of evidence in OLINVYK's post-approval program. The company expects the...
Trevena (NASDAQ:TRVN) has advanced TRV045, a S1P1 receptor modulator, into phase 1 for diabetic neuropathic pain. Trevena will begin a three part-trial: single ascending dose, food effect, and multiple ascending dose. The study will also evaluate whether TRV045 is associat...
3-part randomized, double-blind, placebo-controlled Phase 1 study will evaluate TRV045 safety, tolerability, and PK in healthy volunteers Enrollment expected to start in early Q1 2022 CHESTERBROOK, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a...
News, Short Squeeze, Breakout and More Instantly...
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million reduction in liabilities associated with its ex-US royalty financing ...
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...